US FDA approval for Quo-Test analyser
Download the full announcement
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, announces that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.
The Quo-Test is a fully automated glycated haemoglobin (HbA1c) analyser, providing fast, easy and reliable HbA1c measurement for the monitoring and management of diabetes.
The FDA 510(k) clearance allows the Quo-Test to be used in a laboratory setting for in-vitro quantitative determination of HbA1c in whole blood samples.
For more information on the Quo-Test see: https://www.ekfdiagnostics.com/quo-test.html
Commenting, Julian Baines, CEO of EKF, said:
“We are very pleased with the FDA approval of Quo-Test as this increases the portfolio of products that can now be marketed in the US.”
Enquiries:
EKF Diagnostics Holdings plc |
www.ekfdiagnostics.com Tel: 00 44 29 2071 0570 |
N+1 Singer (Nomad & Broker)
Aubrey Powell / Lauren Kettle / George Tzimas (Corporate Finance) Tom Salvesen (Corporate Broking) |
Tel: 020 7496 3000 |
Walbrook PR Limited |
Tel: 020 7933 8780 or Mob: 07980 541 893 / 07584 391 303 |
Newsletter
Keep up to date with all our activities, events, exhibitions, promotions, investor news & more.